Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: A prospective analysis in a randomized trial

Annals of Hematology

Volumn 90, Issue 12, 2011, Pages 1427-1439

  Verelst, Silvia G R ^a   Termorshuizen, F ^a   Uyl De Groot, C A ^b   Schaafsma, M R ^c   Ammerlaan, A H M ^a   Wittebol, S ^d   Sinnige, H A M ^e   Zweegman, S ^f   Van Marwijk Kooy, M ^g   Van Der Griend, R ^h   Lokhorst, H M ⁱ   Sonneveld, P ^a   Wijermans, P W ^j  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ISALA HOSPITAL   (Netherlands)

^h DEPARTMENT OF SURGERY   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j HAGA HOSPITAL   (Netherlands)

more..

Author keywords

Elderly; Multiple myeloma; Quality of life; Randomized clinical trial; Thalidomide

Indexed keywords

CLODRONIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE;

AGED; BODY IMAGE; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; EMOTION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SOCIAL SUPPORT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE MYELOMA; PREDNISONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84355163112     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1224-1     Document Type: Review

References (19)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 15761078 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi SR Zeldenrust D Dingli SJ Russell JA Lust PR Greipp RA Kyle MA Gertz 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2516 2520 10.1182/blood-2007-10-116129 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
3. RA Kyle MA Gertz TE Witzig JA Lust MQ Lacy A Dispenzieri R Fonseca SV Rajkumar JR Offord DR Larson ME Plevak TM Therneau PR Greipp 2003 Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 1 21 33 12528874 10.4065/78.1.21 (Pubitemid 36033957)
4. T Facon JY Mary C Hulin L Benboubker M Attal B Pegourie M Renaud JL Harousseau G Guillerm C Chaleteix M Dib L Voillat H Maisonneuve J Troncy V Dorvaux M Monconduit C Martin P Casassus J Jaubert H Jardel C Doyen B Kolb B Anglaret B Grosbois I Yakoub-Agha C Mathiot H Avet-Loiseau Intergroupe Francophone du M 2007 Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 9594 1209 1218 10.1016/S0140-6736(07)61537-2 17920916 10.1016/S0140- 6736(07)61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN (Pubitemid 47516593)
5. C Hulin T Facon P Rodon B Pegourie L Benboubker C Doyen M Dib G Guillerm B Salles JP Eschard P Lenain P Casassus I Azais O Decaux L Garderet C Mathiot J Fontan I Lafon JM Virion P Moreau 2009 Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial J Clin Oncol 27 22 3664 3670 10.1200/JCO.2008.21.0948 19451428 10.1200/JCO.2008.21.0948 1:CAS:528:DC%2BD1MXhtVOnu7bJ
6. A Palumbo S Bringhen T Caravita E Merla V Capparella V Callea C Cangialosi M Grasso F Rossini M Galli L Catalano E Zamagni MT Petrucci V De Stefano M Ceccarelli MT Ambrosini I Avonto P Falco G Ciccone AM Liberati P Musto M Boccadoro Italian Multiple Myeloma Network, GIMEMA 2006 Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 9513 825 831 10.1016/S0140-6736(06)68338-4 16530576 10.1016/S0140-6736(06)68338-4 1:CAS:528:DC%2BD28Xit1eht7c%3D (Pubitemid 43363369)
7. A Palumbo S Bringhen AM Liberati T Caravita A Falcone V Callea M Montanaro R Ria A Capaldi R Zambello G Benevolo D Derudas F Dore F Cavallo F Gay P Falco G Ciccone P Musto M Cavo M Boccadoro 2008 Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 112 8 3107 3114 10.1182/blood-2008-04-149427 18505783 10.1182/blood-2008-04-149427 1:CAS:528:DC%2BD1cXht1Omur7P
8. A Waage P Gimsing P Fayers N Abildgaard L Ahlberg B Bjorkstrand K Carlson IM Dahl K Forsberg N Gulbrandsen E Haukas O Hjertner M Hjorth T Karlsson L Knudsen JL Nielsen O Linder UH Mellqvist I Nesthus J Rolke M Strandberg JH Sorbo F Wisloff G Juliusson I Turesson 2010 Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma Blood 10.1182/blood-2009- 08-237974 20448107
9. P Wijermans M Schaafsma F Termorshuizen R Ammerlaan S Wittebol H Sinnige S Zweegman M van Marwijk Kooy R van der Griend H Lokhorst P Sonneveld Dutch-Belgium Cooperative Group HOVON 2010 Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study J Clin Oncol 28 19 3160 3166 10.1200/JCO.2009.26.1610 20516439 10.1200/JCO.2009.26.1610 1:CAS:528: DC%2BC3cXpslajtL8%3D
10. BG Durie SE Salmon 1975 A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 3 842 854 1182674 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 1:STN:280:DyaE28%2FktFCqtA%3D%3D
11. MC Minnema I Breitkreutz JJ Auwerda B van der Holt FW Cremer AM van Marion PH Westveer P Sonneveld H Goldschmidt HM Lokhorst 2004 Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy Leukemia 18 12 2044 2046 10.1038/sj.leu.2403533 15470485 10.1038/sj.leu.2403533 1:CAS:528: DC%2BD2cXhtVSmsrnE (Pubitemid 40028434)
12. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes, et al. 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 5 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
13. K Cocks D Cohen F Wisloff O Sezer S Lee E Hippe P Gimsing I Turesson R Hajek A Smith L Graham A Phillips M Stead G Velikova J Brown Group EQoL 2007 An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma Eur J Cancer 43 11 1670 1678 10.1016/j.ejca.2007.04.022 17574838 10.1016/j.ejca.2007.04.022 1:STN:280:DC%2BD2svhtFelsQ%3D%3D (Pubitemid 47042371)
14. SJ Lee PG Richardson P Sonneveld MW Schuster D Irwin JF San Miguel B Crawford J Massaro R Dhawan S Gupta KC Anderson 2008 Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study Br J Haematol 143 4 511 519 10.1111/j.1365-2141.2008.07378.x 18986387 1:CAS:528:DC%2BD1MXms1Wj
15. AK Kvam P Fayers M Hjermstad N Gulbrandsen F Wisloff 2009 Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations Eur J Haematol 83 4 279 289 10.1111/j.1600-0609.2009.01303.x 19558508 10.1111/j.1600-0609.2009.01303.x
16. B Mohty J El-Cheikh I Yakoub-Agha P Moreau JL Harousseau M Mohty 2010 Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations Haematologica 95 2 311 319 10.3324/haematol.2009. 012674 20139393 10.3324/haematol.2009.012674 1:CAS:528:DC%2BC3cXht1yjtr%2FK
17. A Palumbo F Davies M Kropff J Blade M Delforge F Leal da Costa R Garcia Sanz S Schey T Facon G Morgan P Moreau 2010 Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma Ann Hematol 89 8 803 811 10.1007/s00277-010- 0925-1 20232066 10.1007/s00277-010-0925-1 1:CAS:528:DC%2BC3cXns1yltLw%3D
18. AK Kvam P Fayers F Wisloff 2009 What changes in health-related quality of life matter to multiple myeloma patients? A prospective study Eur J Haematol 10.1111/j.1600-0609.2009.01404.x
19. RA Nout H Putter IM Jurgenliemk-Schulz JJ Jobsen LC Lutgens EM van der Steen-Banasik JW Mens A Slot MC Stenfert Kroese BN van Bunningen VT Smit HW Nijman PP van den Tol CL Creutzberg 2009 Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial J Clin Oncol 27 21 3547 3556 10.1200/JCO.2008.20. 2424 19546404 10.1200/JCO.2008.20.2424